Publications by authors named "Karl Ziegelbauer"

Claim this Profile
B
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.
Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Karl Ziegelbauer

Nat Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.
Volker K Schulze, Ulrich Klar, Dirk Kosemund, Antje M Wengner, Gerhard Siemeister, Karl Ziegelbauer

J Med Chem· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Antje M Wengner, Gerhard Siemeister, Ulrich Lücking, Julien Lefranc, Lars Wortmann, Karl Ziegelbauer

Mol Cancer Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI.
Benjamin Georgi, Johanna Mielke, Mark Chaffin, Amit V Khera, Lian Gelis, Karl Ziegelbauer

Stroke· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Sylvia Grünewald, Oliver Politz, Sebastian Bender, Mélanie Héroult, Klemens Lustig, Karl Ziegelbauer

Int J Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic Effect of a Mesothelin-Targeted Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models.
Katrine Wickstroem, Urs B Hagemann, Véronique Cruciani, Antje M Wengner, Alexander Kristian, Karl Ziegelbauer

J Nucl Med· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Urs B Hagemann, Christine Ellingsen, Joachim Schuhmacher, Alexander Kristian, Anne Mobergslien, Karl Ziegelbauer

Clin Cancer Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate.
Valentina Sica, Jose Manuel Bravo-San Pedro, Valentina Izzo, Jonathan Pol, Sandra Pierredon, Karl Ziegelbauer

Cell Rep· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.
Hung Huynh, Richard Ong, Kah Yong Goh, Liek Yeow Lee, Florian Puehler, Karl Ziegelbauer

Int J Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors and .
Gerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, Wilhelm Bone, Jens Schröder, Karl Ziegelbauer

Clin Cancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
Maria Quanz, Urs B Hagemann, Sabine Zitzmann-Kolbe, Beatrix Stelte-Ludwig, Sven Golfier, Karl Ziegelbauer

Oncotarget· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.
Yasutoshi Kuboki, Christoph A Schatz, Karl Koechert, Sabine Schubert, Janine Feng, Karl Ziegelbauer

Gastric Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
Ulrich Lücking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Dirk Kosemund, Karl Ziegelbauer

ChemMedChem· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.
Mari I Suominen, Katja M Fagerlund, Jukka P Rissanen, Yvonne M Konkol, Jukka P Morko, Karl Ziegelbauer

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
Jörg Willuda, Lars Linden, Hans-Georg Lerchen, Charlotte Kopitz, Beatrix Stelte-Ludwig, Karl Ziegelbauer

Mol Cancer Ther· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Oliver Politz, Franziska Siegel, Lars Bärfacker, Ulf Bömer, Andrea Hägebarth, Karl Ziegelbauer

Int J Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.
Juliane Paul, Maurice Soujon, Antje M Wengner, Sabine Zitzmann-Kolbe, Andrea Sturz, Karl Ziegelbauer

Cancer Cell· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Anette Sommer, Charlotte Kopitz, Christoph A Schatz, Carl F Nising, Christoph Mahlert, Karl Ziegelbauer

Cancer Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitor of NFκB Kinase Subunit 2 Blockade Hinders the Initiation but Aggravates the Progression of Crescentic GN.
Janine Gotot, Eveline Piotrowski, Martin S Otte, André P Tittel, Guo Linlin, Karl Ziegelbauer

J Am Soc Nephrol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.
Antje M Wengner, Gerhard Siemeister, Marcus Koppitz, Volker Schulze, Dirk Kosemund, Karl Ziegelbauer

Mol Cancer Ther· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Julia C Meier, Bernard Haendler, Henrik Seidel, Philip Groth, Robert Adams, Karl Ziegelbauer

Cancer Med· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.
Philine Schneider, Margarete Schön, Nadin Pletz, Cornelia S Seitz, Ningshu Liu, Karl Ziegelbauer

Exp Dermatol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Sven Golfier, Charlotte Kopitz, Antje Kahnert, Iring Heisler, Christoph A Schatz, Karl Ziegelbauer

Mol Cancer Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Roberta Schmieder, Florian Puehler, Roland Neuhaus, Maria Kissel, Alex A Adjei, Karl Ziegelbauer

Neoplasia· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I.
Peter Ellinghaus, Iring Heisler, Kerstin Unterschemmann, Michael Haerter, Hartmut Beck, Karl Ziegelbauer

Cancer Med· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis